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In January 2003, a 55-year old, non-smoking woman visited our hospital to undergo treatment for
T4N0M0 pulmonary adenocarcinoma of the left lung. Until death in October 2015, she received over 20
lines of treatment including a second line therapy with geﬁtinib, which showed long response. In March
2014, she noticed the left axillar lymph node swelling. Aspiration cytology of the lymph node revealed
the presence of adenocarcinoma harboring EGFR exon 19 deletion (Ex19del) but not T790M. Concomitant
ALK translocation of variant 1 was also detected. Crizotinib and alectinib showed marked decrease of
serum CEA value from 731.9 to 122.2 and moderate radiologic response. In contrast, both Ex19del and
T790M, but not ALK translocation, were detected in the metastasis to the left anterior chest wall.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).The activated mutation of epidermal growth factor receptor
(EGFR) and translocation of anaplastic lymphoma kinase (ALK) are
key molecular changes in non-small cell lung cancer (NSCLC).
Tyrosine kinase inhibitors (TKIs) for them, EGFR-TKI and ALK-TKI,
play essential roles in the treatment for NSCLC. Despite conven-
tionally mutually exclusive, concomitant presence of these 2 ge-
netic changes was sporadically reported in NSCLC. For example,
Yang J-J et al. reported that the frequency of the concomitant
presence was approximately 1.3% in 977 consecutive patients with
NSCLC surgical specimens [1]. Lee T et al. reported only 3 cases of
concomitant presence of common EGFR mutation and ALK trans-
location in 6637 NSCLC patients [2]. These mutations are supposed
to be developed through de novo process in this setting, but their
origin is not clear in the patients who underwent preceding TKI
treatments. Actually, gain of activated EGFR mutation is reported
as one of acquired resistance mechanisms for crizotinib, an ALK-
TKI, whereas the opposite is rare. We experienced a NSCLC pa-
tient who had a long-term history of treatment with anti-cancercology, Osaka Medical Center
ichi, Higashinari-ku, Osaka,
mamura).
Ltd. This is an open access article udrugs including EGFR-TKIs, and ﬁnally found that her lung can-
cer carried both an activated EGFR mutation and ALK
translocation.
1. Case report
In January 2003, a 55-year old, non-smoking woman visited
our hospital to undergo treatment for pulmonary adenocarci-
noma of the left lung. Chest computed tomography (CT) sug-
gested the presence of pleural dissemination, which was proved
by video-assisted thoracic surgery (VATS), resulting the stage of
her lung cancer to be T4N0M0 by the TNM staging system at the
time. Until death in October 2015, she received over 20 lines of
treatment. EGFR mutation test was not commercially available in
Japan in 2005. However, geﬁtinib was started as the 2nd line
therapy in October 2005, because she is a non-smoker Japanese
woman. The response to geﬁtinib was shown in Figs. 1A and 2:
Geﬁtinib exhibited prominent effect with a partial response
lasting for 31 months. On the contrary, cytotoxic chemotherapy
was generally less effective for her lung cancer: The durations of
response of the representative chemotherapy regimens such as
carboplatin þ paclitaxel in combination with bevacizumab,
docetaxel, and nab-paclitaxel to be 2M, 14M, and 2M,
respectively.
In March 2014, she noticed the left axillar lymph node (LN)nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Treatment history with an EGFR-TKI and ALK-TKIs. The vertical axis showed
serum CEA values. Arrows indicated by A and B in the upper half show the time when
CT images A and B in Fig. 2 were obtained, respectively. The numbers in the lower half
indicate the time when CT images with the corresponding number in Fig. 3 and 5 were
obtained, respectively. An asterisk indicates a 3rd generation of EGFR-TKI.
Fig. 2. Chest CT images during the treatment with an EGFR-TKI. A) extensive disease
progression throughout in the left thorax before the start of geﬁtinib, and B)
remarkable regression of the disease was attained with geﬁtinib.
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presence of adenocarcinoma cells. Whereas EGFR exon 19 dele-
tion (Ex19del) was detected as expected, a resistance mutation
T790M was not detected. Surprisingly, ALK translocation of
variant 1 was also detected. The presence of ALK translocation
was conﬁrmed by immunocytochemistry (Fig. 4). Neither
immunohistochemistry nor ﬂuorescent in-situ hybridization
(FISH) was performed because of the lack of histologic material.
Crizotinib of 500 mg/day was started as 19th line treatment in
April 2014, which was continued until October 2014, then
changed to alectinib, a second generation ALK-TKI. Serum CEA
value decreased from 731.9 to 122.2 by the treatment with ALK-
TKIs (Fig. 1). Although radiologic regression of the left lung
mass and the left axillar LN was evident (Fig. 3①/②), the lesion
in the left anterior chest wall was gradually increased in size
(Fig. 3①/③). Genetic analysis of this lesion revealed EGFR
Ex19del together with T790M, but ALK translocation could be
detected neither by RT-PCR, immunohistochemistry, nor FISH.
Because of gradual increase of serum CEA value after February
2015, the combination therapy with geﬁtinib and alectinib was
started after the permission of in-house institutional review
board. Her disease was relatively stable for the next 5 months. A
third generation of EGFR-TKI was administered in July 2015,
resulting in regression of lesions in the left lung and left chest
wall. In contrast, the size of the left axillar LN stayed almost the
same (Fig. 5).2. Discussion
Although repetitive genetic testing of driver oncogenes is of
critical importance nowadays, the results is not always simple. In
our patient with a long history of lung cancer treatment including
EGFR-TKIs, concomitant presence of an activated EGFR mutation,
resistant T790M mutation, and ALK translocation was detected.
Whereas T790M will have been dominated through selective
pressure of EGFR-TKIs, the origin of ALK translocation is not clear.
Long treatment history for her lung cancer suggests that cancer
cells with the ALK translocation had not existed at the initial pre-
sentation. Instead, ALK translocation may have developed as an
acquired resistance to EGFR-TKIs.
According to the preceding reports, the effect of ALK inhibitors
on lung cancer which carries concomitant activated EGFR and ALK
translocation is case-dependent: Some investigators observed a
moderate response but the others did not [3e5]. In our patient,
ALK-TKIs were undoubtedly effective, but the responses were
different depending on the lesions. The left axillar LN, which car-
ried translocated ALK, responded to ALK-TKIs, whereas the left
chest wall lesion, which did not carry it, showed no distinct
regression with ALK-TKIs. The fact that the mass in the left lung
regressed in response to ALK-TKIs suggests that the lesion might
also carry translocated ALK. These results indicate that the re-
sponses to ALK-TKIs reﬂected genetic status of each lesion. We tried
the combination of geﬁtinib and alectinib. The combination was
marginally effective.
The better treatment for her diseasemight be a combination of a
3rd generation of EGFR-TKI and an ALK-TKI, because of the presence
of T790M mutation. She underwent a 3rd generation EGFR-TKI as
the 22-th treatment. The response was almost in accordance with
the genetic status of the lesions. The response suggested that the
lesion in the left lung might have contained T790M, although not
tested. Our case suggests that genetic analysis guides the treatment
strategy of lung cancer with multiple drivers. Further accumulation
of treatment experiences is necessary.
Fig. 3. Chest CT images during the treatment with ALK-TKIs and the combination of an EGFR-TKI with an ALK-TKI. Arrow heads in the right, central, and left column indicate the
lesion in the left lung, a left axillar lymph node, and a metastatic lesion to the thoracic wall, respectively.
Fig. 4. Immunocytochemical staining with an ALK antibody (Roche D5F3F). Almost all cancer cells were positive for ALK.
Fig. 5. Chest CT images before (4) and during (5) the treatment with a 3rd generation EGFR-TKI. Each column corresponds to that in Fig. 3. Appreciable response was observed.
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